Lawrence F. Eichenfield

Guest Editor for the following articles:

Vol. 36. No. 3

Curriculum United for Better Eczema Care: why, how, and what?

Andrea Waldman, MD | David Fleischer, MD | Dawn Marie Davis, MD | Jonathan Spergel, PhD | Jusleen Ahluwalia, MD | Lawrence F. Eichenfield, MD
While various medical specialties treat eczema patients, care for these patients is largely fragmented and disorganized.
Vol. 36. No. 4

Emerging Science and Management of Atopic Dermatitis, Introduction

Lawrence F. Eichenfield, MD

The landscape of atopic dermatitis has evolved rapidly in recent years. The introduction of crisaborole, a  phosphodiesterase-4 inhibitor, enables clinicians to offer another nonsteroidal topical therapy to patients with mild to moderate disease. The approval of dupilumab—an interleukin-4 and interleukin-13 inhibitor and the first biologic to become available for the  treatment of atopic dermatitis—has revolutionized the therapy of adults with moderate to severe disease.